How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/early-breast-cancer-hormone-receptor-positive-and-postmenopausal.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Early Breast Cancer Hormone Receptor Positive and Postmenopausal — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Early Breast Cancer Hormone Receptor Positive and Postmenopausal (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Early Breast Cancer Hormone Receptor Positive and Postmenopausal, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Femara	letrozole	Novartis AG	Aromatase Inhibitor [EPC]	aromatase enzyme		1997-07-25
Femara	Femara	M.D. Anderson Cancer Center		Cytochrome P450 11B2, mitochondrial, Aromatase, Cytochrome P450 11B1, mitochondrial

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

M.D. Anderson Cancer Center · 1 drug in Early Breast Cancer Hormone Receptor Positive and Postmenopausal
Novartis AG · 1 drug in Early Breast Cancer Hormone Receptor Positive and Postmenopausal

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Early Breast Cancer Hormone Receptor Positive and Postmenopausal:

Cite this brief

Drug Landscape (2026). Early Breast Cancer Hormone Receptor Positive and Postmenopausal — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/early-breast-cancer-hormone-receptor-positive-and-postmenopausal. Accessed 2026-06-10.

Early Breast Cancer Hormone Receptor Positive and Postmenopausal full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing